1. Home
  2. Medical oncology
  3. Neurological
  4. Glioma

Glioma high grade recurrent PCV (procarbazine lomustine vinCRISTine) DISCONTINUED

Check for clinical trials in this patient group. Link to Australian Clinical Trials opens in a new tab or window website

On this page
Expand all Collapse all Back to top
It is the consensus opinion of the Medical Oncology Reference Committee to discontinue this protocol due to no clinical need.

Treatment schedule summary

Drug Dose Route Day
Lomustine 110 mg/m2 ONCE a day PO 1
vinCRISTine 1.4 mg/m2 (cap dose at 2 mg) IV infusion 8 and 29
Procarbazine 60 mg/m2 ONCE a day PO 8 to 21

Frequency: 6 weeks

Cycles: Continuous until disease progression or unacceptable toxicity (up to 6 cycles)

Note: the doses of the drugs in this protocol are different from those used in the trial;r these protocol doses have been used in the adjuvant setting and it is the consensus of the eviQ Reference Committee to use the same drug doses for the PCV protocol in the recurrent setting. Dosing may require rounding to the nearest capsule strength to enable delivery of a measurable dose.

[%id%]
[%title%] [%url%]

Flinders Filters has partnered with eviQ to build reliable, robust search filters to retrieve core high level evidence on topics of significance to eviQ. The project goal is the provision of a sustainable model for evidence retrieval to ensure ongoing currency of content.

These search filters have been developed to retrieve the most up to date evidence from PubMed, in real time, using specifically designed search filters built to meet our needs.   

Searches can be used when a protocol is scheduled for review or at any time you choose. Please click on this link opens in a new tab or window to access the Pubmed searches.

Access Flinders Filters opens in a new tab or window, a division of the Flinders Digital Health Research Centre at Flinders University to read more about research solutions to searching problems.

Troubleshooting

Occasionally the searches may not display correctly or take too long to load (and will eventually timeout). This may be caused by Internet Explorer being unable to handle long URL's. You can rectify this by using Firefox, Safari or Google chrome. It is always a good idea to clear the cache regularly to ensure you are getting the most up to date search.

Feedback

If you identify any new articles that you believe should be included in the content, please use the feedback button below to inform us of the name of the article(s). 

Version 7

Date Summary of changes
19/03/2025

Protocol reviewed at the Neurological Reference Committee meeting on 21/02/2025. Protocol discontinued due to no clinical need. Version number changed to V.7.

Version 6

Date Summary of changes
18/06/2024

Protocol updated with ADDIKD guideline recommendations. New kidney dosing recommendation table added to dose modification section.

Version number changed to V.6.

Version 5

Date Summary of changes
16/03/2023 Protocol reviewed at Medical Oncology Reference Committee meeting. Consensus of the reference committee to SUPERSEDE this protocol as superior alternatives available. Version increased to V.5. Next review in 4 years.
10/01/2024 Drug cost updated to exclude procarbazine and lomustine cost.

Version 4

Date Summary of changes
12/09/2014 New protocol taken to Medical Oncology Reference Committee meeting.
31/10/2014 Approved and published on eviQ.
15/05/2015 Skin rash (Dryness, Erythema and Pruritus) removed.
31/05/2017

Transferred to new eviQ website. Protocol version number changed to V.2.

Hepatitis B screening changed to NOT recommended

Diluent volume of vincristine changed from ‘50 to 100 mL’ to ‘50 mL’ as per Australian Injectable Handbook Sixth Edition.
18/01/2018 Protocol reviewed at Medical Oncology Reference Committee meeting on 18/08/17. The following changes were made: 
  • Title updated to include "high grade" 
  • Indication updated
  • Peripheral neuropathy clinical information and dose modifications updated (made consistent with other vincristine protocols on eviQ)
  • Protocol version number increased to V.3. 

Review protocol again in 2 years
10/05/2018 Haematological dose modifications updated as per consensus of the expert clinician group. Version number changed to V.4.
13/11/2018 Protocol updated due to discontinuation of lomustine 100mg capsules
14/06/2019

Protocol reviewed electronically by the Medical Oncology Reference Committee. No changes. Review 2 years
01/05/2021 Protocol reviewed electronically by Medical Oncology Reference Committee. No changes. Next review in 2 years.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page

First approved:
Last reviewed:
Superseded:
Discontinued:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/1673

15 Jun 2025